7 reports

The magnitude of the impact has been categorized as described below: Low Moderate - Medium-level impact on the market High - Negligible or no impact on the market landscape - Very high impact, with radical influence on the growth of the market ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Colorectal Cancer
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck Serono S.A.
  • Medical Care 12%

Its highest selling products include Betaferon/ Betaseron (multiple sclerosis); YAZ/ Yasmin/ Yasminelle (hormonal contraceptive); Kogenate (hemophilia); Nexavar (cancer); Adalat (hypertension); and Mirena (hormonal contraceptive).

  • Colorectal Cancer
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Sanofi S.A.

The prominent features of this report are - ##.

  • Colorectal Cancer
  • Therapy
  • World
  • Product Initiative
  • Novartis AG

It acts as inhibitor of mitogen activated protein Kinase-##/ ## (MEK ##/ ##).

  • Cancer
  • Colorectal Cancer
  • Targeted Therapy
  • United States
  • Novartis AG

GlaxoSmithKline registered a Phase I open-label, non-randomized, sequential, two-period, repeat-dose study to evaluate the pharmacokinetics and safety of trametinib on combined oral contraceptive (norethindrone plus ethinyl estradiol) in female subjects with solid tumors.

  • Cancer
  • Colorectal Cancer
  • Targeted Therapy
  • United States
  • Novartis AG

Median follow-up was ## ## months (IQR ## ##-## ##).

  • Colorectal Cancer
  • Lung Cancer
  • United States
  • Company Operations
  • Product Initiative
  • COLORECTAL CANCER - PIPELINE BY KURA ONCOLOGY INC
  • COLORECTAL CANCER - PIPELINE BY LABORATORIO ELEA SACIF Y A

IT ALSO OFFERS PRODUCTS FOR THERAPEUTIC AREAS SUCH AS HIPOLIPEMIANTES, ANTIBIOTICOS, AIDS, BONE CALCIUM REGULATORS, FERTILITY, HORMONE THERAPY, LAXATIVES, PARKINSON' S DISEASE, CONTRACEPTIVES, AND ANTIVIRAL, AMONG OTHERS.

  • Colorectal Cancer
  • Pharmaceutical
  • Targeted Therapy
  • Product Initiative
  • Merck & Co., Inc.